Lung volume reduction surgery for advanced emphysema
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ipg114
2 The procedure
2.1.1 Emphysema is a chronic lung disease. The walls of the air sacs (alveoli) in the lung weaken and disintegrate, leaving behind abnormally large air spaces that remain filled with air even when the patient breathes out. These air spaces may coalesce to form larger air-filled sacs called bullae. The surface area of the alveoli is decreased, so there is less space for the exchange of oxygen and carbon dioxide. This leads to reduced levels of oxygen in the blood. The most common symptoms of emphysema are shortness of breath (dyspnoea), coughing, fatigue and weight loss.
2.1.2 Emphysema often co-exists with chronic bronchitis. Both of these conditions may be described by the more general term of chronic obstructive pulmonary disease (COPD).
2.1.3 Treatment for COPD involves a multidisciplinary approach, which may include education, exercise, breathing retraining, smoking cessation, oral and inhaled medication, oxygen therapy, and lung transplantation. Lung volume reduction surgery may be an option for patients with severe symptoms for whom conservative treatments have proved inadequate.
2.2.1 Lung volume reduction surgery is a palliative treatment that aims to remove the least functional part of the lungs. Computed tomography (CT) and perfusion scanning are used to identify the diseased lung tissue. The diseased part of the lung can be accessed by various techniques including median sternotomy, video-assisted thoracoscopy and thoracotomy. The first two are the most common techniques. Median sternotomy involves cutting through the sternum to open the chest. The video-assisted procedure involves making a number of small incisions in both sides of the chest to allow the insertion of instruments into the chest between the ribs. A thoracotomy involves making an incision between the ribs on one side of the chest and separating the ribs to access the lung.
2.2.2 The aim of the surgery is to reduce the volume of the lung. This is done by using a surgical stapling device to cut and seal the tissue, laser ablation to shrink lung volume, or a combination of both. Once the tissue has been removed, the lung is re-inflated and the chest closed.
2.3.1 Evidence on efficacy indicates that in certain patients lung function, exercise performance and quality of life are improved in the short term after lung volume reduction surgery. These results have been relatively consistent across study designs and were confirmed in the National Emphysema Treatment Trial, a recent large-scale randomised controlled trial comparing surgery with medical therapy.
2.3.2 The National Emphysema Treatment Trial randomised 1218 patients, of whom 580 underwent surgery. At 24 months, exercise capacity had improved in 15% (54/371) of patients in the surgery group compared with 3% (10/378) of patients in the medical group (p < 0.001). Quality of life had also improved in the surgical group (121/371) as compared with the medical group (34/378) at 24 months (33% versus 9%, p < 0.001). However, the trial found no difference in overall mortality between the two groups (0.11 deaths per person-year, risk ratio 1.01, p = 0.90). For more details, refer to the Sources of evidence section.
2.3.3 The Specialist Advisors considered that the procedure is beneficial for a select proportion of patients, but the benefit tends to decline with time.
2.4.1 The most common complication was persistent air leak from the lung. In one study of 250 patients, 45% (113/250) of patients experienced prolonged air leaks lasting more than 7 days, with 8 of these patients (3%) requiring a subsequent operation. Other complications in this series included pneumonia 10% (24/250), in-hospital mortality 5% (12/250), myocardial infarction 2% (5/250), deep vein thrombosis 2% (4/250), small bowel obstruction 2% (6/250) and phrenic nerve injury < 1% (2/250). For more details, refer to the Sources of evidence section.
2.4.2 Complications include those that may arise from pre-existing co-morbidities as well as those that are directly due to the surgery.
2.4.3 The Specialist Advisors considered that the risks of surgery were well known. They listed the main complications as being air leaks, chest infections and respiratory failure.